<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847143</url>
  </required_header>
  <id_info>
    <org_study_id>P/2014/237</org_study_id>
    <nct_id>NCT02847143</nct_id>
  </id_info>
  <brief_title>Ocytocine and Cerebral Activation in Relation With Attachement</brief_title>
  <acronym>OTACLA</acronym>
  <official_title>A Cross Over Randomized Controlled Trial of the Effect of Nasal Ocytocine on Cerebral Activations in Relation With Attachement in the General Population</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to characterize the cerebral activation modifications related to nasal
      oxytocin administration during vizualisation of distress images in population of healthy
      people with different attachement styles.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adult male will be recruited. Their attachement style will be assessed through the
      Attachement scale interview (ASI).

      They will have 2 fMRI sessions, during which emotional images will be presented.

      One session will be preceded by a nasal administration of oxytocin and the other session will
      be preceded by a placebo nasal administration. The order of both administrations will be
      randomized.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>BOLD signal intensity</measure>
    <time_frame>45 min after intranasal administration of oxytocin or placebo</time_frame>
    <description>BOLD signal will be assessed in the brain regions associated with attachement: amygdala, medial prefrontal cortex and dorsolateral prefrontal cortex.
Both conditions (placebo vs axytocin) will be compared in the four groups. BOLD signal will be assessed during the visualization of emotional pictures that ellicit distress, comfort or complicity or neural emotion.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Attachement Style</condition>
  <arm_group>
    <arm_group_label>secure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy adult male with secure attachement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>avoidant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy adult male with avoidant attachement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>enmeshed/fearfull</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy adult male with enmeshed/fearfull attachement</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dual style</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>healthy adult male with dual attachement style</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nasal oxytocin or placebo</intervention_name>
    <description>nasal administration of oxytocin or palcebo 45 min befor fMRI session</description>
    <arm_group_label>secure</arm_group_label>
    <arm_group_label>avoidant</arm_group_label>
    <arm_group_label>enmeshed/fearfull</arm_group_label>
    <arm_group_label>dual style</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>fMRI</intervention_name>
    <description>FMRI during emotional image visualization</description>
    <arm_group_label>secure</arm_group_label>
    <arm_group_label>avoidant</arm_group_label>
    <arm_group_label>enmeshed/fearfull</arm_group_label>
    <arm_group_label>dual style</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Attachement scale interview (ASI)</intervention_name>
    <description>this scale is used to determine the attachement style of each participant</description>
    <arm_group_label>secure</arm_group_label>
    <arm_group_label>avoidant</arm_group_label>
    <arm_group_label>enmeshed/fearfull</arm_group_label>
    <arm_group_label>dual style</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>psychometric scales</intervention_name>
    <description>self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)</description>
    <arm_group_label>secure</arm_group_label>
    <arm_group_label>avoidant</arm_group_label>
    <arm_group_label>enmeshed/fearfull</arm_group_label>
    <arm_group_label>dual style</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  comprehension of french

          -  having signed the informed consent

        Exclusion Criteria:

          -  chronic disease (liver failure, kidney failure) and cardiovascular disease

          -  hypertensive treatment

          -  treatment wich increases QT

          -  current hospitalisation

          -  fMRI contraindication

          -  legal protection
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauriane VULLIEZ-COADY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Besancon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauriane VULLIEZ-COADY, MD</last_name>
    <email>lvulliez@chu-besancon.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Julie MONNIN, PhD</last_name>
    <email>jmonnin@chu-besancon.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHU Besancon</name>
      <address>
        <city>Besancon</city>
        <state>Doubs</state>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Monnin, PhD</last_name>
      <phone>00033381218543</phone>
      <email>jmonnin@chu-besancon.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2016</study_first_posted>
  <last_update_submitted>July 21, 2017</last_update_submitted>
  <last_update_submitted_qc>July 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Attachement</keyword>
  <keyword>Oxytocin</keyword>
  <keyword>fMRI</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

